HO, Chris,LIEBERMAN, Harvey,PHILBROOK, C. Michael,SANTOS, Michael,YANG, Donglai
申请号：
TN2017000234
公开号：
TN2017000234A1
申请日:
2015.12.17
申请国别(地区):
TN
年份:
2018
代理人:
摘要：
Pharmaceutical formulations with a tropomyosin-related kinase inhibitor ("Trk inhibitor") are disclosed. The pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine in microcrystalline suspension formulations in its monohydrate form, which shows improved characteristics over the anhydrate form, and in extended release formulations. The extended release pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine-loaded microspheres.
